

Press Release

**Global Pharma business meets YTD Dec '13 Guidance,
Revenues at INR 1,035 Crores with an EBITDA of INR 201 Crores***

Current Financial Year extended by 3 months, to end in Mar'14

**Guides Revenues of INR 280 Crores and EBITDA in the range of
INR 58-60 Crores for the extended quarter ending Mar '14**

*Adjusted for Exchange, YTD Dec'13 EBITDA at INR 223 Crs

Bangalore, February 7, 2014 Strides Arcolab (BSE: 532531, NSE: STAR) today announced its financial results for the Quarter ended December 31, 2013.

Highlights


Source: Management Accounts

Global Pharma

- Three notch upgrade from BBB+ to A+ (in Jan'14) by India Ratings (a Fitch Group company)
- Revenue Guidance of Rs. 1,000 Crs & EBITDA guidance of Rs. 200 Crs met despite delays in anticipated product approvals from USFDA
- Consolidated Pharma Revenues for YTD Dec'13 at Rs.1,035 Crores with an EBITDA of Rs.201 Crores, impacted by an Exchange Loss of Rs.22 Crores (EBITDA Margin of 19%)
- Adjusted for Exchange Loss, YTD Dec'13 EBITDA at Rs.223 Crores, EBITDA Margin of 22%
- Q4'13 Consolidated Pharma Revenues at Rs.326 Crores with an EBITDA of Rs.60 Crores
- Q4'13 Consolidated Pharma EBITDA grew by 100+% (Rs.60 Crores in Q4 2013 against Rs.28 Crores in Q4 2012)
- Strong offtake in Institutional business with the launch of recently approved Anti-Malarial product
- 47 filings as on date with USFDA with 18 pending approvals

Biotech

- Stelis Biopharma entered into a long-term agreement with Germany's Pieris AG for worldwide development and commercialisation of a protein molecule, primarily focused on ophthalmology.



“This has been a defining quarter for all of us at Strides as we delivered significant value to all stakeholders post the successful completion of the Agila transaction. The continuing global pharma business has delivered the 12 month guidance despite delays in key product approvals from USFDA. We expect to continue the momentum in the coming quarters.” said Arun Kumar, Vice Chairman and Group CEO, Strides Arcolab Limited.

Standalone Financials

(Rupees in Crores)

	YTD Dec '13	YTD Dec '12	Growth %
Revenues	876	774	13%
EBITDA	186	158	18%
PBT	4,679	60	100+%
PAT	3,561	56	100+%
EPS	Rs.602.79	Rs. 9.55	100+%

(Rupees in Crores)

	Q4 '13	Q4'12	Growth %
Revenues	276	229	20%
EBITDA	50	61	-17%
PBT	4,643	78	100+%
PAT	3,525	74	100+%
EPS	Rs.597	Rs.12.58	100+%

Source: unaudited standalone financials


Note: Financial year changed from Jan-Dec to April-March in line with the new Companies Act. Current Financial year will be for 15 months ending March 2014

About Strides Arcolab

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products.

The Company has 5 manufacturing facilities presence in more than 75 countries in developed and emerging markets.

Additional information is available at the Company's website at www.stridesarco.com.



For further information, please contact:

<u>Strides</u> Badree Komandur, CFO +91 80 6784 0747 <u>Investors:</u> Mr. Kannan. N: +91 98450 54745 Mr. Vikesh Kumar +91 80 6784 0827	<u>PR Consultancy</u> Weber Shandwick Kaveri Mandanna: +91 90089 59697 KMandanna@webershandwick.com Mahesh Nair: +91 98803 76648 MNair@webershandwick.com
--	---

